Skip to main content
. 2018 Nov 25;38:100–112. doi: 10.1016/j.ebiom.2018.11.004

Fig. 4.

Fig. 4

miR-1246 inhibitor in combination with paclitaxel greatly reduced tumor growth in a SKOV3-ip1 mouse model.a. (Top) Comparison of the tumors obtained from representative mice treated with CTL miRNA inhibitor or miR-1246 inhibitor in DOPC particles as well as groups treated with each inhibitor in combination with paclitaxel. (Bottom) Tumor weights for groups treated with CTL miRNA inhibitor or miR-1246 inhibitor in combination with paclitaxel were significantly different (p < 0.05). b. There was a decreasing pattern in number of nodules in mice treated with CTL miRNA inhibitor vs miR-1246 inhibitor and with each inhibitor in combination with paclitaxel (p = n.s.). c. Mouse body weights show that there was no toxicity issue for any of the groups at the end of the treatment period. d. Immunohistochemical staining for a marker of proliferating cells (Ki67). e, f. Cav1 (e) and PDGFRβ (f) expression in tumors from mice treated with CTL miRNA inhibitor, miR-1246 inhibitor, or either inhibitor combined with paclitaxel. *p < 0.05, ** p < 0.005 (t-test), data are presented as mean ± SD.